Cassava Sciences Licenses Simufilam Method of Treatment Patent

Core Viewpoint - Cassava Sciences has entered into a licensing agreement with Yale University for intellectual property rights related to simufilam, aimed at treating seizures associated with rare neurodevelopmental disorders, particularly tuberous sclerosis complex (TSC) [1][3]. Group 1: Licensing Agreement - The agreement includes an exclusive license to US method of treatment patent (US 12,186,307) for simufilam [1][8]. - The licensed intellectual property is based on research conducted by Dr. Angélique Bordey and her team at Yale, which demonstrated that simufilam significantly reduced seizure frequency in an animal model [2][3]. Group 2: Research and Development - Cassava plans to conduct preclinical studies in collaboration with the TSC Alliance to further evaluate simufilam's potential as a treatment for TSC-related seizures [3]. - Simufilam is a proprietary investigational oral small molecule that targets the filamin A protein [4][9]. Group 3: Tuberous Sclerosis Complex (TSC) - TSC is a neurodevelopmental disorder caused by mutations in the mTOR pathway genes, leading to seizures in 80% to 90% of patients [5][6]. - Approximately two-thirds of TSC patients do not respond to current antiepileptic drugs, resulting in lifelong seizures and associated disabilities [6]. Group 4: Market Potential - TSC affects an estimated 1 in 6,000 live births, with around 50,000 individuals in the United States and over one million worldwide living with the condition [7].